نتایج جستجو برای: ماتریس mds

تعداد نتایج: 16566  

2015
Abdallah Abou Zahr Ehab Saad Aldin Rami S Komrokji Amer M Zeidan

Myelodysplastic syndromes (MDS) represent a heterogeneous group of acquired clonal hematopoietic disorders characterized by peripheral blood cytopenias, paradoxical BM hypercellularity, ineffective hematopoiesis, and increased risk of leukemic transformation. Risk stratification, using different prognostic scores and markers, is at the core of MDS management. Deletion 5q [del(5q)] MDS is a dist...

2016
Lisa Pleyer Sonja Burgstaller Reinhard Stauder Michael Girschikofsky Heinz Sill Konstantin Schlick Josef Thaler Britta Halter Sigrid Machherndl-Spandl Armin Zebisch Angelika Pichler Michael Pfeilstöcker Eva-Maria Autzinger Alois Lang Klaus Geissler Daniela Voskova Dietmar Geissler Wolfgang R. Sperr Sabine Hojas Inga M. Rogulj Johannes Andel Richard Greil

BACKGROUND The MDS-IWG and NCCN currently endorse both FAB and WHO classifications of MDS and AML, thus allowing patients with 20-30 % bone marrow blasts (AML20-30, formerly MDS-RAEB-t) to be categorised and treated as either MDS or AML. In addition, an artificial distinction between AML20-30 and AML30+ was made by regulatory agencies by initially restricting approval of azacitidine to AML20-30...

2014
Levi J. Beverly Daniel T. Starczynowski

Myelodysplastic syndromes (MDS) are a collection of hematopoietic stem cell (HSC) disorders that consist of blood cytopenias, marrow dysplasia, and a predisposition to acute myeloid leukemia (AML). Approximately 30% of MDS patients go on to develop aggressive AML. MDS is fatal in a majority of patients as a result of marrow failure, immune dysfunction, and/or transformation to overt leukemia. A...

2011
Vincent Mor Orna Intrator Mark Aaron Unruh Shubing Cai

BACKGROUND The Minimum Data Set (MDS) for nursing home resident assessment has been required in all U.S. nursing homes since 1990 and has been universally computerized since 1998. Initially intended to structure clinical care planning, uses of the MDS expanded to include policy applications such as case-mix reimbursement, quality monitoring and research. The purpose of this paper is to summariz...

Journal: :CoRR 2015
Chin Hei Chan Maosheng Xiong

Maximum-distance separable (MDS) convolutional codes form an optimal family of convolutional codes, the study of which is of great importance. There are very few general algebraic constructions of MDS convolutional codes. In this paper, we construct a large family of unit-memory MDS convolutional codes over Fq with flexible parameters. Compared with previous works, the field size q required to ...

Journal: :Anticancer research 2012
Takahiro Yamauchi Yasufumi Matsuda Mihoko Takai Toshiki Tasaki Naoko Hosono Eiju Negoro Satoshi Ikegaya Kazutaka Takagi Shinji Kishi Akira Yoshida Yoshimasa Urasaki Takanori Ueda

BACKGROUND/AIM Pancytopenia is caused by acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), aplastic anemia (AA), or by non-hematological diseases. Because Wilms' tumor-1 (WT1) is overexpressed in patients with AML and MDS, its expression level may be helpful for diagnosing these hematological malignancies. PATIENTS AND METHODS We retrospectively investigated the WT1 transcripts in...

2013
George I. Mias Rui Chen Yan Zhang Kunju Sridhar Donald Sharon Li Xiao Hogune Im Michael P. Snyder Peter L. Greenberg

Increased autoantibody reactivity in plasma from Myelodysplastic Syndromes (MDS) patients may provide novel disease signatures, and possible early detection. In a two-stage study we investigated Immunoglobulin G reactivity in plasma from MDS, Acute Myeloid Leukemia post MDS patients, and a healthy cohort. In exploratory Stage I we utilized high-throughput protein arrays to identify 35 high-inte...

2010
Francesco D’Alò Mariangela Greco Marianna Criscuolo Maria Teresa Voso

In the last decade, significant advances have been made in the treatment of patients with Myelodysplastic Syndromes (MDS). Although best supportive care continues to have an important role in the management of MDS, to date the therapeutic approach is diversified according to the IPSS risk group, karyotype, patient's age, comorbidities, and compliance. Hematopoietic growth factors play a major r...

2013
Shyamala C. Navada

Myelodysplastic syndrome (MDS) represents a heterogeneous hematopoietic stem-cell disorder that results in abnormal cellular maturation and peripheral blood cytopenias. MDS is characterized by progressive bone marrow failure, which can lead to bleeding, infections, and complications secondary to anemia. Approximately 35% to 40% of patients diagnosed with MDS progress to acute myeloid leukemia (...

2005
Alexander Sternberg Sally Killick Tim Littlewood Chris Hatton Andy Peniket Thomas Seidl Shamit Soneji Joanne Leach David Bowen Claire Chapman Graham Standen Edwin Massey Lisa Robinson Bipin Vadher Richard Kaczmarski Riaz Janmohammed Kim Clipsham Andrew Carr Paresh Vyas

Early, low-risk International Prognostic Scoring System (IPSS) myelodysplastic syndrome (MDS) is a heterogeneous disorder where the molecular and cellular hematopoietic defects are poorly understood. To gain insight into this condition, we analyzed gene expression profiles of marrow CD34 progenitor cells from normal-karyotype, low-blast-count MDS patients, age-matched controls, and patients wit...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید